SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market cap as key catalysts for significant potential upside. The community is actively discussing the possibility of a major price breakout, with many drawing comparisons to previous market cycles and pinning hopes on upcoming exchange listings or an broader resurgence in the NFT sector.

Welcome to the fabulous world of OKANE, where wealth meets wagging tails!   Inspired by the Japanese word for "money," OKANE is more than just a meme coin; it’s a celebration of all things cute, quirky, and oh-so-luxurious.  Meet our charming mascot, a pampered pup with a flair for the extravagant. With his sparkling collar and stylish shades, this adorable canine knows how to live the high life. Whether he’s lounging in a sun-soaked doggy mansion or attending exclusive puppy parties, our little tycoon embodies the spirit of prosperity and joy.

OKANE

OKANE is generating speculative interest as traders track its technical ranges and build-up beneath key resistance levels. Market participants are actively debating the token's distribution among top holders while weighing its momentum against various other altcoin opportunities.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for the community due to renewed institutional interest and a wave of activity surrounding its potential in real-world asset (RWA) tokenization and post-quantum security research. Investors are actively debating the long-term viability of the project, weighing concerns over its historical price performance against optimism that new governance developments and potential regulatory clarity will drive future utility.

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is seeing heightened community discussion and investor focus as market participants eagerly await Phase 3 data readouts for its lead candidate, Duravyu, for wet AMD, which are anticipated mid-2026. The community is closely analyzing institutional accumulation, the company's competitive positioning against similar TKI-based therapies, and potential regulatory inflection points, while recent earnings volatility has fueled debate over the firm's cash runway and long-term valuation.

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Eton Pharmaceuticals Inc

Eton Pharmaceuticals is currently trending due to its recent FDA approval for DESMODA, a milestone that community members view as a significant step in the company's evolution from a biotech hopeful to a revenue-generating commercial player. The community is actively discussing the stock's potential as an undervalued "hidden gem," citing strong recent financial performance, successful portfolio expansion, and an upcoming earnings report as key drivers for potential long-term growth.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is seeing heightened trader attention as the community debates its potential as a high-performance Layer 1 alternative to established networks like Ethereum and Solana. Discussions are currently dominated by a mix of long-term optimism regarding its ecosystem growth and staking utility versus concerns over recent price volatility and token distribution schedules.

EOG Resources, Inc. engages in the exploration, development, production and marketing of crude oil and natural gas. It operates through the United States, Trinidad, and Other International geographical segments. The Other International segment includes China and Canada operations. The company was founded in 1985 and is headquartered in Houston, TX.

EOG Resources, Inc.

EOG Resources is trending as investors weigh recent analyst target increases against a broader energy sector landscape shaped by robust production efficiency and global supply volatility. The community remains focused on the company's strong operational fundamentals and its strategy of returning capital to shareholders through dividends and opportunistic repurchases.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in community interest driven by anticipation of upcoming cannabis-related catalysts and the approach of annual industry milestones. Supporters are actively highlighting the project's organic growth and long-term vision, positioning it as a culture-driven alternative to traditional cannabis stocks.

Pump.fun

Pump.fun is trending as investors weigh its role in memecoin volatility against its high-volume performance on the Solana network, with communities actively debating the balance between gambling risks and the potential for organic viral growth. Discussion remains polarized, centered on intense community-led projects like $PMV and $WAGMI, which traders are using to anchor conversations around long-term conviction and culture-driven market movement.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is seeing significant community discussion driven by its status as a major DeFi project on the Avalanche network, with investors closely watching its total value locked and potential for real-world asset integration. While some holders express frustration over recent price volatility and accumulation struggles, many participants remain optimistic about its long-term utility and ecosystem growth alongside AVAX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market

Key PointsThe market for weight loss drugs still has plenty of room to grow...

Novo Nordisk A/S $NVO Stock Position Lifted by Banque Pictet & Cie SA

Banque Pictet & Cie SA grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 68.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm...

Novo Nordisk A/S (NYSE:NVO) Receives Average Rating of "Hold" from Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) have been assigned an average rating of "Hold" from the twenty-four brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nineteen have given a hold rating and fou...

Novo Nordisk (NVO) Rises Higher Than Market: Key Facts

Novo Nordisk (NVO) closed at $36.98 in the latest trading session, marking a +1.37% move from the prior day.

Novo Nordisk A/S (NYSE:NVO) Shares Up 1.2%  - Time to Buy?

Novo Nordisk A/S (NYSE:NVO) Trading 1.2% Higher - Here's Why...

Novo Nordisk claims Wegovy shows greater weight loss than Eli Lilly's rival pill

A cross-trial comparison shows Novo's oral semaglutide produced three percentage points more weight loss and fewer dropouts due to side effects...

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.

<ul class="summary-bullets"><li>Results from the ORION study showed that using semaglutide led to about 3 percentage points more weight loss on average.</li><li>In a separate patient survey, 84% of participants preferred a treatment profile similar to semaglutide over orforglipron, Novo said.</li><li>The study used a population-adjusted indirect treatment comparison to measure weight loss and tolerability between oral semaglutide 25 mg and orforglipron 36 mg.</li></ul>Novo Nordisk (NVO) on Thursday said that oral semaglutide 25 mg delivered greater weight loss than orforglipron, just a day after the U.S. Food and Drug Administration <a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-rallies-on-much-awaited-fda-approval-for-weight-loss-pill/cZ7Hp5ORIF5">approved</a> Eli Lilly’s weight loss drug.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> was little changed at the time of writing while <a href="https://stocktwits.com/symbol/LLY">LLY shares</a> fell more than 1%.Results from the ORION study showed semaglutide led to about 3 percentage points more weight loss on average, Novo said. The FDA approved orforglipron at doses up to 17.2 mg. The approved 17.2 mg tablet is equivalent to the 36 mg capsules used in Phase 3 trials, which were used as the comparator in the ORION study.The ORION study used a population-adjusted indirect treatment comparison to measure weight loss and tolerability between oral semaglutide 25 mg and orforglipron 36 mg. It was based on data from the Phase 3 OASIS 4 and ATTAIN-1 clinical trials.<h2 class="st-heading-2">Discontinuation Rates Roughly 14 Times Higher With orforglipron</h2>The study also found tolerability advantages for semaglutide. Patients taking orforglipron had significantly higher odds of stopping treatment due to side effects, especially gastrointestinal (GI) issues. Discontinuation rates due to GI events were roughly 14 times higher with orforglipron.In a separate patient survey, 84% of participants preferred a treatment profile similar to semaglutide over orforglipron.<h2 class="st-heading-2">Novo’s Discounted Offering&nbsp;</h2>Earlier this week, Novo Nordisk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-offers-discounted-subscription-plan-for-us-patients-using-wegovy/cZEPHskRIVf">introduced&nbsp;</a>a discounted subscription plan for U.S. patients paying out of pocket for its obesity drug Wegovy, aiming to better compete with Eli Lilly.&nbsp;Monthly pricing for Wegovy injections now ranges from $329 for a three-month plan to $249 for a one-year plan, compared with the usual $349, while the pill version is priced between $249 and $289 per month.By comparison, Eli Lilly’s self-pay pricing for Zepbound starts at $299 per month for the 2.5 mg dose and increases to $399 for 5 mg, $449 for 7.5 mg, with higher doses priced further up.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for NVO on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.One&nbsp; user said Novo’s data was a “big distortion.”<stembedurl>https://stocktwits.com/stockanalyst8/message/649299985</stembedurl>However, another user said that the latest data “could&nbsp;limit sales for orforglipron.<stembedurl>https://stocktwits.com/MStocktwit/message/649293749</stembedurl>Year-to-date the NVO shares have declined nearly 30% while LLY stock has shed more than 13%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Highlights Semaglutide Edge A Day After FDA Clears Lilly’s Orforglipron

The study also showed discontinuation rates due to gastrointestinal events were roughly 14 times higher with orforglipron.

GLP-1 Rivalry Heats Up: Novo Nordisk Claims Lead Over Lilly’s Newly Approved Pill

Equity

Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era...

Lilly (LLY) Surges 3.8%: Is This an Indication of Further Gains?

Lilly (LLY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Stocktwits

Stocktwits Polls

Novo Nordisk A/S

Intense market competition between industry giants has traders debating which pill-based weight loss treatment holds the long-term crown.

Bullish investors are highlighting historical lows and attractive price-to-earnings ratios, viewing the current downtrend as an entry opportunity.

Ongoing discussions revolve around manufacturing capacity and whether current infrastructure can handle the massive surge in expected demand.

Traders are closely analyzing indirect trial comparisons between competing treatments to see which shows superior efficacy and tolerability.

Current Price	$36.98
Prev Close	$36.48
Open	$36.09
Dividend Yield	2.53%
50-Day Moving Average	$44.19
Beta	0.91
Avg. Volume	19.26M
PE Ratio	10.65

52-Week High	$81.44
52-Week Low	$35.12
Market Capitalization	$124.59B
EPS (Annual)	$3.49
Price to Book	5.39
Revenue Per Employee	$679,358.45

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVONovo Nordisk A/S